-
Hsin-Wei Chen,
Hsin-Yu Chen,
Li-Tzu Wang,
Fu-Hui Wang,
Li-Wen Fang,
Hsiu-Yu Lai,
Hsuan-Hsu Chen,
Jean Lu,
Ming-Shiu Hung,
Yao Cheng,
Mei-Yu Chen,
Shih-Jen Liu,
Pele Chong,
Oscar Kuang-Sheng Lee,
Shu-Ching Hsu
[show abstract]
[hide abstract]
ABSTRACT: Mesenchymal stem/stromal cells (MSCs) are promising potential candidates for the treatment of immunological diseases because of their immunosuppressive functions. However, the molecular mechanisms that mediate MSCs' immunosuppressive activity remain elusive. In this article, we report for the first time, to our knowledge, that secreted growth-regulated oncogene (GRO) chemokines, specifically GRO-γ, in human MSC-conditioned media have an effect on the differentiation and the function of human monocyte-derived dendritic cells. The monocyte-derived dendritic cells were driven toward a myeloid-derived suppressor cell (MDSC)-like phenotype by the GRO chemokines. GRO-γ-treated MDSCs had a tolerogenic phenotype that was characterized by an increase in the secretion of IL-10 and IL-4, and a reduction in the production of IL-12 and IFN-γ. We have also shown that the mRNA expression levels of the arginase-1 and inducible NO synthase genes, which characterize MDSCs, were upregulated by GRO-γ-primed mouse bone marrow cells. In addition, the ability of GRO-γ-treated bone marrow-derived dendritic cells to stimulate the OVA-specific CD8(+) T (OT-1) cell proliferation and the cytokine production of IFN-γ and TNF-α were significantly decreased in vivo. Our findings allow a greater understanding of how MDSCs can be generated and offer new perspectives to exploit the potential of MDSCs for alternative approaches to treat chronic inflammation and autoimmunity, as well as for the prevention of transplant rejection.
The Journal of Immunology 04/2013; · 5.79 Impact Factor
-
Hsin-Wei Chen,
Shih-Jen Liu,
Yi-Shiuan Li,
Hsueh-Hung Liu,
Jy-Ping Tsai,
Chen-Yi Chiang,
Mei-Yu Chen,
Chyi-Sing Hwang,
Chin-Cheng Huang,
Hui-Mei Hu,
Han-Hsuan Chung,
Sze-Hsien Wu,
Pele Chong,
Chih-Hsiang Leng,
Chien-Hsiung Pan
[show abstract]
[hide abstract]
ABSTRACT: We have previously demonstrated that vaccination with a subunit dengue vaccine containing a consensus envelope domain III with aluminum phosphate elicits neutralizing antibodies against all four serotypes of dengue virus in mice. In this study, we evaluated the immunogenicity of the subunit dengue vaccine in non-human primates. After vaccination, monkeys that received the subunit vaccine with aluminum phosphate developed a significantly strong and long-lasting antibody response. A specific T cell response with cytokine production was also induced, and this correlated with the antibody response. Additionally, neutralizing antibodies against serotype 2 were detected in two of three monkeys. The increase in serotype-2-specific antibody titers and avidity observed in these two monkeys suggested that a serotype-2-biased antibody response occurs. These data provide evidence that a protective neutralizing antibody response was successfully elicited in non-human primates by the dengue subunit vaccine with aluminum phosphate adjuvant.
Archives of Virology 03/2013; · 2.11 Impact Factor
-
Jy-Ping Tsai,
Meng-Hua Lee,
Shu-Ching Hsu,
Mei-Yu Chen,
Shih-Jen Liu,
Joseph T Chang,
Chun-Ta Liao,
Ann-Joy Cheng,
Pele Chong,
Ching-Liang Chu,
Chia-Rui Shen, Hsin-Wei Chen
[show abstract]
[hide abstract]
ABSTRACT: Previous studies have shown that TGF-β acts cooperatively with IL-6 to elicit a high frequency of IL-17-secreting CD4(+) T cells (termed Th17) and an elevated CD8(+)IL-17(+) T cell population (termed Tc17). These CD8(+) cells fail to behave like most cytotoxic T lymphocytes that express IFN-γ and granzyme B, but they exhibit a noncytotoxic phenotype. Although a significant increase in the number of these Tc17 cells was found in tumors, their role and interaction with other cell types remain unclear. In this study, we demonstrate that the presence of CD4(+)CD25(-) T cells, but not the CD4(+)CD25(+) (regulatory T [Treg]) cell population, significantly reduced the elicitation of Tc17 cells, possibly as a result of the induction of apoptotic signals. Importantly, these signals may be derived from soluble mediators, and the addition of anti-IL-2 restored the reduction of Tc17 cells in the presence of CD4(+)CD25(-) T cells. Finally, the elicited Tc17 and Treg cells exhibited a close association in patients with head and neck cancer, indicating that the surrounding Treg cells might maintain the survival of the Tc17 cells. Taken together, these results reveal an intriguing mechanism in which Tc17 cells are controlled by a finely tuned collaboration between the different types of CD4(+) T cells in distinct tumor microenvironments.
The Journal of Immunology 07/2012; 189(4):1671-9. · 5.79 Impact Factor
-
Chen-Yi Chiang,
Ming-Hsi Huang,
Chun-Hsiang Hsieh,
Mei-Yu Chen,
Hsueh-Hung Liu,
Jy-Ping Tsai,
Yi-Shiuan Li,
Ching-Yun Chang,
Shih-Jen Liu,
Pele Chong,
Chih-Hsiang Leng, Hsin-Wei Chen
[show abstract]
[hide abstract]
ABSTRACT: The major weaknesses of subunit vaccines are their low immunogenicity and poor efficacy. Adjuvants can help to overcome some of these inherent defects with subunit vaccines. Here, we evaluated the efficacy of the newly developed water-in-oil-in-water multiphase emulsion system, termed PELC, in potentiating the protective capacity of dengue-1 envelope protein domain III. Unlike aluminum phosphate, dengue-1 envelope protein domain III formulated with PELC plus CpG oligodeoxynucleotides induced neutralizing antibodies against dengue-1 virus and increased the splenocyte secretion of IFN-γ after in vitro re-stimulation. The induced antibodies contained both the IgG1 and IgG2a subclasses. A rapid anamnestic neutralizing antibody response against a live dengue virus challenge was elicited at week 26 after the first immunization. These results demonstrate that PELC plus CpG oligodeoxynucleotides broaden the dengue-1 envelope protein domain III-specific immune responses. PELC plus CpG oligodeoxynucleotides is a promising adjuvant for recombinant protein based vaccination against dengue virus.
PLoS Neglected Tropical Diseases 05/2012; 6(5):e1645. · 4.69 Impact Factor
-
Shih-Hsin Tu,
Hsing-I Huang,
Su-I Lin,
Hsin-Yu Liu,
Yuh-Pyng Sher,
Sheng-Kuo Chiang,
Pele Chong,
Steve Roffler,
Guan-Chin Tseng, Hsin-Wei Chen,
Shih-Jen Liu
[show abstract]
[hide abstract]
ABSTRACT: Vaccines utilizing cytotoxic T lymphocyte (CTL) epitopes are promising for the treatment of cancer and chronic infectious diseases. Tumor-associated antigen L6 (TAL6) is overexpressed in some epithelial cancer cells. In this report, we detected TAL6 expression in breast cancer tissue using quantitative reverse-transcriptase-polymerase chain reaction. We found that >80% of breast tumor tissue highly expressed TAL6 compared with adjacent normal breast tissue. To identify CTL epitopes from TAL6, we synthesized 18 peptides for HLA-A2-binding assay based on the MHC-binding motif using 4 computer prediction programs. Positive binders identified by ELISA were immunized in HLA-A2 transgenic (A2 Tg) mice. Two peptides, peptide 2 and peptide 5, induced T-cell responses in A2 Tg mice. To confirm whether these peptides could be processed and presented to induce T-cell responses in vivo, A2 Tg mice were immunized with plasmid DNA encoding TAL6. We found that both peptides 2 and 5 stimulated splenocytes from TAL6-immunized mice to secrete interferon-γ. However, only peptide 5 could induce expression of the cytolytic molecule CD107a on CD8+ T cells after immunization. Furthermore, peptide 5-immunized A2 Tg mice could inhibit the growth of TAL6-positive tumors (EL4/TAL6/HLA-A2) in A2 Tg mice but not in wild-type mice. These results demonstrate that the TAL6-derived CTL epitope could induce HLA-A2-restricted immunity against TAL6-expressing tumor cells.
Journal of immunotherapy (Hagerstown, Md.: 1997) 04/2012; 35(3):235-44. · 3.20 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Mesenchymal stem cells (MSCs) are multi-potent with numerous mesenchymal-lineage differentiation potential and immunomodulatory capabilities. However, the immunoregulatory properties of MSCs are not clearly defined. The objective of the present study was to elucidate the role(s) of MSCs in IL-17 production and the subsequent effect(s) on neutrophil activation. We have demonstrated that human bone marrow-derived MSCs (BM-MSCs) instruct anti-CD3/anti-CD28 antibody-activated CD4(+) CD45RO(+) memory T cells, but not other CD4(+) subsets or CD8(+) T cells, to produce IL-17 after cell-cell contact. After the addition of IL-17, neutrophil phagocytic activity was increased. This is the first report on the ability of BM-MSCs to induce IL-17 production in memory CD4(+) T cells that, in turn, promotes enhanced phagocytic activity of neutrophils. These results suggest that MSCs regulate the functional activation of neutrophils via their role in modulating IL-17 from CD4(+) CD45RO(+) memory T cells.
Immunobiology 02/2012; · 3.20 Impact Factor
-
Kuo-Shu Tsai,
Shung-Haur Yang,
Yen-Ping Lei,
Chih-Chien Tsai, Hsin-Wei Chen,
Chih-Yuan Hsu,
Ling-Lan Chen,
Hsei-Wei Wang,
Stephanie A Miller,
Shih-Hwa Chiou,
Mien-Chie Hung,
Shih-Chieh Hung
[show abstract]
[hide abstract]
ABSTRACT: Tumor-initiating cells are a subset of tumor cells with the ability to form new tumors; however, they account for less than 0.001% of the cells in colorectal or other types of tumors. Mesenchymal stem cells (MSCs) integrate into the colorectal tumor stroma; we investigated their involvement in tumor initiation.
Human colorectal cancer cells, MSCs, and a mixture of both cell types were injected subcutaneously into immunodeficient mice. We compared the ability of each injection to form tumors and investigated the signaling pathway involved in tumor initiation.
A small number (≤ 10) of unsorted, CD133⁻, CD166⁻, epithelial cell adhesion molecule⁻(EpCAM⁻), or CD133⁻/CD166⁻/EpCAM⁻ colorectal cancer cells, when mixed with otherwise nontumorigenic MSCs, formed tumors in mice. Secretion of interleukin (IL)-6 by MSCs increased the expression of CD133 and activation of Janus kinase 2-signal transducer and activator of transcription 3 (STAT3) in the cancer cells, and promoted sphere and tumor formation. An antibody against IL-6 or lentiviral-mediated transduction of an interfering RNA against IL-6 in MSCs or STAT3 in cancer cells prevented the ability of MSCs to promote sphere formation and tumor initiation.
IL-6, secreted by MSCs, signals through STAT3 to increase the numbers of colorectal tumor-initiating cells and promote tumor formation. Reagents developed to disrupt this process might be developed to treat patients with colorectal cancer.
Gastroenterology 05/2011; 141(3):1046-56. · 11.68 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: To protect against dengue viral infection, a novel lipidated dengue subunit vaccine was rationally designed to contain the consensus amino acid sequences derived from four serotypes of dengue viruses. We found that the lipidated consensus dengue virus envelope protein domain III (LcED III) is capable of activating antigen-presenting cells and enhancing cellular and humoral immune responses. A single-dose of LcED III immunization in mice without extra adjuvant formulation is sufficient to elicit neutralizing antibodies against all four serotypes of dengue viruses. In addition, strong memory responses were elicited in mice immunized with a single-dose of LcED III. Quick, anamnestic neutralizing antibody responses to a live dengue virus challenge were elicited at week 28 post-immunization. These results demonstrate the promising possibility of a future successful tetravalent vaccine against dengue viral infections that utilizes one-dose vaccination with LcED III.
PLoS ONE 01/2011; 6(8):e23319. · 4.09 Impact Factor
-
Tu-Lai Yew,
Yeh-Ting Hung,
Hsin-Yang Li, Hsin-Wei Chen,
Ling-Lan Chen,
Kuo-Shu Tsai,
Shih-Hwa Chiou,
Kuan-Chong Chao,
Tung-Fu Huang,
Hen-Li Chen,
Shih-Chieh Hung
[show abstract]
[hide abstract]
ABSTRACT: Wound healing can be improved by transplanting mesenchymal stem cells (MSCs). In this study, we have demonstrated the benefits of the conditioned medium derived from human MSCs (CM-MSC) in wound healing using an excisional wound model. CM-MSC accelerated wound closure with increased reepithelialization, cell infiltration, granulation formation, and angiogenesis. Notably, CM-MSC enhanced epithelial and endothelial cell migration, suggesting the contribution of increased cell migration to wound healing enhanced by CM-MSC. Cytokine array, ELISA analysis, and quantitative RT-PCR revealed high levels of IL-6 in CM-MSC. Moreover, IL-6 added to the preconditioned medium enhanced both cell migration and wound healing, and antibodies against IL-6 blocked the increase in cell motility and wound closure by CM-MSC. The IL-6 secretory pathway of MSCs was inhibited by SB203580, an inhibitor of p38 MAPK or siRNA against p38 MAPK, suggesting IL-6 secretion by MSCs is mediated through the activation of p38 MAPK. Inactivation of p38 MAPK also reduced the expression and production of IL-8 and CXCL1 by MSCs, both of which were also demonstrated to enhance cell migration and wound closure. Thus, our data suggest MSCs promote wound healing through releasing a repertoire of paracrine factors via activation of p38 MAPK, and the CM-MSC may be applied to enhance wound healing.
Cell Transplantation 12/2010; 20(5):693-706. · 5.13 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: The role of interleukin (IL)-21 in influencing tumor growth or enhancing anti-tumor immunity is somewhat controversial. To further understand the potential regulatory effects of IL-21, we utilized an IL-21-secreting EG7 tumor model to demonstrate the direct effects of IL-21 on host tumor-infiltrating lymphocyte (TIL) profiles. Vector control EG7 cells (EG7-Vec) produced very low amounts of IL-21 and were highly tumorigenic. In contrast, IL-21-expressing EG7 cells, EG7-IL-21L and EG7-IL-21H, secreted relatively and extremely high levels of IL-21, respectively. Most importantly, both IL-21-expressing EG7 cells' control of tumor growth was not due to increased proliferative ability of tumor cells, but resulted from the induction of cytotoxic cellular responses in immunocompetent mice. To identify the effects of cancer immunoediting, tumor-infiltrating lymphocyte profiles were analyzed. NK cell populations appeared to be increased in EG7-IL-21H tumor sites at days 6-8 (progression stage), though this phenomenon did not persist at days 10-12 (regression stage). However, at both days 6-8 and 10-12, a higher frequency of CD8(+) T cells was observed at the tumor site in EG7-IL-21H-inoculated mice than in EG7-Vec-inoculated mice. These findings suggest that NK cell-mediated tumor rejection may efficiently drive the development of tumor-specific cytotoxic T cell responses with the help of elevated IL-21 expression. These results also suggest the therapeutic potential of IL-21.
Immunobiology 09/2010; 216(4):491-6. · 3.20 Impact Factor
-
Chih-Hsiang Leng, Hsin-Wei Chen,
Li-Sheng Chang,
Hsueh-Hung Liu,
Hsin-Yu Liu,
Yuh-Pyng Sher,
Yu-Wen Chang,
Shu-Pei Lien,
Tzu-Yi Huang,
Mei-Yu Chen,
Ai-Hsiang Chou,
Pele Chong,
Shih-Jen Liu
[show abstract]
[hide abstract]
ABSTRACT: The lipid moiety of a novel recombinant lipoprotein, which contains a dengue virus envelope protein domain 3, rlipo-D1E3, has been shown to activate antigen-presenting cells (APCs) as an intrinsic adjuvant. Because the lipid moiety of rlipo-D1E3 contains an unsaturated fatty acid, it is unclear if the receptor usage by bacterially derived lipoproteins is the same as that of the synthetic lipopeptide palmitoyl-3-Cys-Ser-(Lys)(4) (Pam3). In the present study, we show that the rlipo-D1E3 lipoprotein can induce the activation of spleen cells and bone marrow-derived dendritic cells (BM-DCs) in wild-type and TLR4-deficient mice, but not in TLR2(-/-) mice. After analyzing the co-receptor usage of TLR2 using TLR1(-/-) or TLR6(-/-) mice, the TLR2 signaling triggered by rlipo-D1E3 and Pam3 could use either TLR1 or TLR6 as a co-receptor. Analysis of the MAPK signaling pathway revealed that rlipo-D1E3 could initiate the phosphorylation of p38, ERK1/2 and JNK1/2 earlier than the synthetic lipopeptide. In addition, the expression levels of IL-23, IL-27 and MIP-1 alpha in BM-DCs stimulated by rlipo-D1E3 were higher than the expression levels in BM-DCs stimulated by Pam3. Taken together, these results demonstrate that different TLR2 ligands can promote various immune responses by inducing different levels of biological cytokines and chemokines.
Molecular Immunology 07/2010; 47(11-12):2015-21. · 2.90 Impact Factor
-
Ming-Hsi Huang,
Su-Chen Lin,
Chia-Hsin Hsiao,
Hsin-Ju Chao,
Hung-Ren Yang,
Chien-Chun Liao,
Po-Wei Chuang,
Huang-Pi Wu,
Chiung-Yi Huang,
Chih-Hsiang Leng,
Shih-Jen Liu, Hsin-Wei Chen,
Ai-Hsiang Chou,
Alan Yung-Chih Hu,
Pele Chong
[show abstract]
[hide abstract]
ABSTRACT: Antigen sparing and cross-protective immunity are regarded as crucial in pandemic influenza vaccine development. Both targets can be achieved by adjuvantation strategy to elicit a robust and broadened immune response. We assessed the immunogenicity of an inactivated H5N1 whole-virion vaccine (A/Vietnam/1194/2004 NIBRG-14, clade 1) formulated with emulsified nanoparticles and investigated whether it can induce cross-clade protecting immunity.
After formulation with PELC, a proprietary water-in-oil-in-water nanoemulsion comprising of bioresorbable polymer/Span(R)85/squalene, inactivated virus was intramuscularly administered to mice in either one-dose or two-dose schedule. We found that the antigen-specific serum antibody responses elicited after two doses of non-adjuvanted vaccine were lower than those observed after a single dose of adjuvanted vaccine, PELC and the conventional alum adjuvant as well. Moreover, 5 microg HA of PELC-formulated inactivated virus were capable of inducing higher antibodies than those obtained from alum-adjuvanted vaccine. In single-dose study, we found that encapsulating inactivated virus into emulsified PELC nanoparticles could induce better antibody responses than those formulated with PELC-adsorbed vaccine. However, the potency was rather reduced when the inactivated virus and CpG (an immunostimulatory oligodeoxynucleotide containing unmethylated cytosine-guanosine motifs) were co-encapsulated within the emulsion. Finally, the mice who received PELC/CpG(adsorption)-vaccine could easily and quickly reach 100% of seroprotection against a homologous virus strain and effective cross-protection against a heterologous virus strain (A/Whooper swan/Mongolia/244/2005, clade 2.2).
Encapsulating inactivated H5N1 influenza virus and CpG into emulsified nanoparticles critically influences the humoral responses against pandemic influenza. These results demonstrated that the use of PELC could be as antigen-sparing in preparation for a potential shortage of prophylactic vaccines against local infectious diseases, in particular pandemic influenza. Moreover, the cross-clade neutralizing antibody responses data verify the potential of such adjuvanted H5N1 candidate vaccine as an effective tool in pre-pandemic preparedness.
PLoS ONE 01/2010; 5(8):e12279. · 4.09 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: This study presents an efficient and sensitive method for detecting rare cells without cell culture, in which cells are analyzed quantitatively using quantum dots (QDs) as a fluorescent probe. By the conjugation of QDs with cells, the biotin-streptavidin reaction functions as a bridge to connect QDs and cells. The cells can be quantified based on the correlation of the QD fluorescence intensity with the cell population. Non-specific adsorption and cross-reaction of QD625-streptavidin on T cell membrane are neglected by reacting with biotin anti-human CD3 and mixing with red blood cell, respectively. Additionally, the photo-activation period and pH can be controlled to enhance the fluorescence of cell populations, which increases linearly with the number of T cells from 40 to 100,000, not only in a single T cell line but also in mixing with a total of 10(6) red blood cells. Moreover, the specific T cells can be detected in less than 15 min, even though rare specific cells may number only 40 cells. Among the advantages, the proposed system for detecting rare cells include simplicity of preparation, low cost, rapid detection, and high sensitivity, all of which can facilitate the detection of circulating tumor cells in early stages of diagnosis or prognosis.
Analytical and Bioanalytical Chemistry 12/2009; 396(3):1135-41. · 3.78 Impact Factor
-
Hsin-Wei Chen,
Chih-Hsiang Leng,
Hsin-Yu Liu,
Wen-Fang Cheng,
Yu-Wen Chang,
Pin-Yi Wu,
Shu-Pei Lien,
Tzu-Yi Huang,
Sheng-Kuo Chiang,
Min-Han Lin,
Mi-Hua Tao,
Pele Chong,
Shih-Jen Liu
[show abstract]
[hide abstract]
ABSTRACT: Identification of the cytotoxic T lymphocyte (CTL) epitopes of tumor antigens is important for effective immunotherapy. We report that a combination of epitope prediction, enzyme-linked immunosorbent assay (ELISA)-based epitope-HLA complex formation, and DNA immunization methods can improve the efficiency and accuracy of CTL epitope studies. In this study, two HLA-A11-restricted epitopes derived from human papillomavirus (HPV)18 E6 oncoprotein were identified. HLA-A11-transgenic mice immunized with these epitopes could specifically induce interferon-gamma (IFNgamma) production, cytotoxicity and peptide/HLA-A11 tetramer binding in CD8(+) T-cells. To study intracellular processing of CTL epitopes, we constructed a DNA plasmid containing an endoplasmic reticulum (ER) targeting sequence as well as the HPV18 E6 and E7 genes (pEK/HPV18E6E7). CTL responses against peptide-pulsed T2/A11 cells could be detected after immunizing HLA-A11-transgenic mice with pEK/HPV18E6E7. Furthermore, the identified peptides could stimulate T-cells to secrete IFNgamma from HPV18-infected patients. Our results demonstrate that the antigenic E6 peptides derived from HPV18 are potential candidates for the treatment of HPV 18-associated tumors in HLA-A11(+) populations.
Cancer biology & therapy 12/2009; 8(21):2025-32. · 2.64 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: IL-6 is a proinflammatory cytokine secreted by tumor cells and immune cells to affect the development of cancer. This study demonstrates the effects of tumor-derived IL-6 on the malignancy of tumor cells and tumor immunity. The tumor cell line, EG7, was transfected with a mammalian expression vector encoding the full length of murine IL-6 to mimic IL-6-secreting tumor cells. Two IL-6 transfectants with low and high IL-6 production were compared in vitro and in vivo. While the in vitro proliferation rates of both transfectants and the parental line were similar, high expression of IL-6 induced a significant reduction in tumor growth in vivo. Concomitantly, there was an increase in IFN-gamma positive tumor-infiltrating lymphocytes and a decrease in the suppressive CD4(+)CD25(+)FoxP3(+) population. These results demonstrate the direct effects of tumor-derived IL-6 on cancer development and the induction of tumor immunity.
Immunobiology 09/2009; 215(6):486-91. · 3.20 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: To enhance the water affinity of W/O emulsion-adjuvanted vaccines, we used three bioresorbable polymers named PEG-b-PLA, PEG-b-PCL, and PEG-b-PLACL as hydrophilic emulsifier to stabilize the interfaces between the oily Montanide ISA 51 adjuvant and the antigen media.
Polymers were synthesized by ring-opening polymerization of lactide and/or epsilon-caprolactone in the presence of monomethoxy PEG. (1)H NMR and GPC data showed that obtained polymers consisted of 70 wt.% hydrophilic PEG block and 30 wt.% lipophilic PLA, PCL, PLACL block with molecular weights of 7,000.
The polymer-stabilized ISA51 emulsions have high affinity to water, such that the stock of antigen-encapsulating emulsion could be re-dispersed into PBS before injection, thus yielding stable and injectable W/O/W emulsion nanoparticles. Immunogenicity studies showed that PEG-b-PLACL/ISA51/PBS-formulated ovalbumin with only 5% of ISA51 oily adjuvant could induce the same level of antibody titers as those induced by PBS/ISA51-formulated ovalbumin.
The novel multi-phase emulsions increase fluidity and conceptually diminish local reactions with respect to the W/O type vaccines produced from the same oil. These features are of great interest for applications in candidate vaccine delivery, especially for further optimization of alternative immunization routes, such as intramuscular, transdermal or mucosal administration.
Pharmaceutical Research 06/2009; 26(8):1856-62. · 4.09 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Vaccine shortages are a major obstacle to influenza pandemic preparedness. Increasing vaccine efficiency provides a potentially effective way to overcome this problem. Specifically, using single-dose immunization to induce protective immunity is an attractive approach to emergency/massive vaccination. In this report, we propose a novel nanoemulsion comprised of the bioresorbable polymer, Span 85, and squalene forming a ready-to-use adjuvant, called PELC. After formulation with PELC, inactivated H5N1 virus was intramuscularly administered to mice via a single injection. The data demonstrate that inactivated virus containing 0.5microg hemagglutinin (HA) and formulated with PELC induced more potent antigen-specific antibodies, hemagglutination inhibition, and virus neutralization than non-adjuvanted inactivated virus containing 5microg HA. In addition, T-cell proliferative responses, as well as interferon-gamma (IFN-gamma) and interleukin-4 (IL-4) secretion were significantly enhanced after immunization with PELC-adjuvanted inactivated virus. These results indicate that PELC can be used for effective single-dose immunization and could thus play an important role in influenza pandemic preparedness.
Microbes and Infection 05/2009; 11(6-7):654-60. · 3.10 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Novel emulsion-type vaccine delivery systems based on the amphiphilic bioresorbable polymer poly(ethylene glycol)-block-poly(lactide-co-epsilon-caprolactone) (PEG-b-PLACL) and selected oils were developed here. Physicochemical characterizations such as stability, a droplet test, microscopic aspects, and in vitro release showed that PEG-b-PLACL-emulsified formulations have several advantages over traditional vaccine adjuvants in that they are stable, reproducible, and homogeneous fine particles with an appropriate size to facilitate the induction of potent immune responses. Different dispersion-type emulsions have provided different release profiles using ovalbumin in model studies. Immunogenicity studies in mice have shown that antigen-specific antibody titers and T-cell proliferative responses, as well as the secretion of IFN-gamma, were significantly enhanced for ovalbumin after formulation with PEG-b-PLACL-based emulsions. These features are of great interest for applications in delivery systems of prophylactic and therapeutic vaccine candidates.
Journal of Biomedical Materials Research Part B Applied Biomaterials 04/2009; 90(2):832-41. · 2.15 Impact Factor
-
Fang-Feng Chiu,
Nandini Venkatesan,
Chia-Rong Wu,
Ai-Hsiang Chou, Hsin-Wei Chen,
Shu-Pei Lian,
Shih-Jen Liu,
Chin-Cheng Huang,
Wei-Cheng Lian,
Pele Chong,
Chih-Hsiang Leng
[show abstract]
[hide abstract]
ABSTRACT: The neutralization titer of a hemagglutinin (HA)-specific neutralizing antibody against new isolates reflect both the antigenic drift and the conformation status of HA protein in these new influenza viruses. Since most antigenic sites are in the HA1 domain of HA, using HA1 domain of influenza virus as antigen is of great importance in vaccine development. In this study, we investigate different purification processes for optimizing the immunological properties of an Escherichia coli-expressed HA1 domain (rH5HA1) of influenza H5N1 virus. rH5HA1 was expressed as inclusion bodies and extracted with 6M guanidine hydrochloride (GnHCl)/PBS buffer. The best condition for generating HA1-specific neutralization determinants is on-column oxidative refolding procedures with GSH/GSSG and l-arginine buffer. Others refolding procedures such as using high-pH buffer and/or different detergent solubilizations were found to be ineffective producing neutralization epitope recognized by a HA1-specific neutralizing monoclonal antibody that was raised against H5N1 virus.
Biochemical and Biophysical Research Communications 04/2009; 383(1):27-31. · 2.48 Impact Factor
-
Hsin-Wei Chen,
Shih-Jen Liu,
Hsueh-Hung Liu,
Yan Kwok,
Chang-Ling Lin,
Li-Hsiu Lin,
Mei-Yu Chen,
Jy-Ping Tsai,
Li-Sheng Chang,
Fang-Feng Chiu,
Li-wei Lai,
Wei-Cheng Lian,
Chiou-Ying Yang,
Shih-Yang Hsieh,
Pele Chong,
Chih-Hsiang Leng
[show abstract]
[hide abstract]
ABSTRACT: We have developed a novel platform technology that can express high levels of recombinant lipoproteins with intrinsic adjuvant properties. In this study, Ag473 (a lipoprotein from Neisseria meningitidis) can be produced in high yields using Escherichia coli strain C43 (DE3). After testing a non-lipoimmunogen (E3, from dengue virus) fused with different lipid signal peptides from other lipoproteins as well as Ag473 fragments of different lengths, we identified that the fusion sequence has to contain at least the N-terminal 40 residues, D1, of Ag473 to achieve high expression levels of the recombinant lipo-immunogen (rlipo-D1E3). The rlipo-D1E3 was found to elicit stronger anti-E3 and virus neutralizing antibody responses in animal studies than those from rE3 alone or rE3 formulated with alum adjuvant. These results have successfully demonstrated the merit of lipo-immunogens for novel vaccine development.
Vaccine 02/2009; 27(9):1400-9. · 3.77 Impact Factor
